Eli Lilly (LLY) Other Working Capital Changes (2009 - 2026)

Eli Lilly has reported Other Working Capital Changes for 18 years, with the latest figure at -$175.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Working Capital Changes fell 136.92% year-over-year to -$175.0 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 billion (up 69.97% YoY), and the FY2025 full-year result was $6.6 billion, up 98.41% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at -$175.0 million, down from $5.9 billion in the prior quarter.
• The five-year high for Other Working Capital Changes was $5.9 billion in Q4 2025, with the low at -$4.9 billion in Q3 2025.
• Historically, Other Working Capital Changes has averaged $639.9 million across 5 years, with a median of $298.6 million in 2024.
• Annual changes were most pronounced in 2023 — Other Working Capital Changes tumbled 319.57% — and 2025, when it surged 16253.92%.
• Eli Lilly's Other Working Capital Changes stood at $481.4 million in 2022, then fell by 9.39% to $436.2 million in 2023, then slumped by 60.82% to $170.9 million in 2024, then soared by 3368.4% to $5.9 billion in 2025, then slumped by 102.95% to -$175.0 million in 2026.
• The last three Other Working Capital Changes figures came in at -$175.0 million (Q1 2026), $5.9 billion (Q4 2025), and -$4.9 billion (Q3 2025), per Business Quant data.